OPKO Health (OPK) Misses Q3 EPS by 3c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
OPKO Health (OPK) Submitted PMA Application with FDA for Point-of-Care PSA Test with Claros 1 Platform
November 7, 2017 8:17 AM ESTOPKO Health, Inc. (NASDAQ: OPK) announces the filing of a Premarket Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for the Total PSA test with the Claros® 1 immunoassay analyzer. The filing contains clinical data from the Companys 864-patient Total PSA clinical study.
The Claros 1 immunoassay analyzer is a novel diagnostic instrument system that can provide rapid, quantitative blood test results in 10 minutes right in the physicians office. The Claros 1 incorporates cutting edge microfluidics in a credit card sized disposable test... More
